RxSight, Inc. (NASDAQ:RXST – Get Free Report) CFO Shelley B. Thunen sold 10,000 shares of RxSight stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $52.69, for a total transaction of $526,900.00. Following the transaction, the chief financial officer now directly owns 13,938 shares of the company’s stock, valued at $734,393.22. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
RxSight Price Performance
Shares of RXST stock opened at $61.68 on Friday. The company has a market cap of $2.29 billion, a P/E ratio of -43.13 and a beta of 1.21. The stock’s 50-day moving average is $52.59 and its 200 day moving average is $42.56. RxSight, Inc. has a 1-year low of $18.09 and a 1-year high of $61.85.
RxSight (NASDAQ:RXST – Get Free Report) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.10. The business had revenue of $28.58 million for the quarter, compared to analysts’ expectations of $28.60 million. RxSight had a negative net margin of 54.57% and a negative return on equity of 31.16%. On average, analysts anticipate that RxSight, Inc. will post -0.94 EPS for the current year.
Institutional Trading of RxSight
Wall Street Analysts Forecast Growth
Several research analysts have issued reports on the company. Oppenheimer boosted their target price on RxSight from $54.00 to $61.00 and gave the company an “outperform” rating in a research report on Thursday, February 29th. Needham & Company LLC reissued a “buy” rating and issued a $64.00 price objective on shares of RxSight in a research note on Thursday, April 11th. Stifel Nicolaus raised their price target on RxSight from $54.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. Finally, JPMorgan Chase & Co. upped their price objective on shares of RxSight from $40.00 to $62.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $49.63.
View Our Latest Stock Report on RxSight
About RxSight
RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Further Reading
- Five stocks we like better than RxSight
- When to Sell a Stock for Profit or Loss
- Appleās Earnings Show Investors Its Strength and Its Weakness
- With Risk Tolerance, One Size Does Not Fit All
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- How to Use High Beta Stocks to Maximize Your Investing Profits
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.